Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 26:10:36-40.
doi: 10.1016/j.jbo.2017.11.005. eCollection 2018 Mar.

Advances in limb salvage treatment of osteosarcoma

Affiliations
Review

Advances in limb salvage treatment of osteosarcoma

Yichun Yang et al. J Bone Oncol. .

Abstract

Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade.

Keywords: Chemotherapy; Infection; Limb salvage; Osteosarcoma; Surgery.

PubMed Disclaimer

References

    1. Bielack S., Carrle D., Casali P.G. Osteosarcoma: esmo clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009;20(4):137–139. - PubMed
    1. Ottaviani G., Jaffe N. The etiology of osteosarcoma. Cancer Treat. Res. 2009;152:15–32. - PubMed
    1. Dhammi I.K., Kumar S. Osteosarcoma: a journey from amputation to limb salvage. Indian J. Orthop. 2014;48(3):233–234. - PMC - PubMed
    1. Ferrari S., Ruggieri P., Cefalo G., Tamburini A., Capanna R., Fagioli F., Comandone A., Bertulli R., Bisogno G., Palmerini E., Alberghini M., Parafioriti A., Linari A., Picci P., Bacci G. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an italian sarcoma group trial isg/os-1. J. Clin. Oncol. 2012;30(17):2112–2118. - PubMed
    1. Rothwell P.M., Wilson M., Price J.F., Belch J.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–1601. - PubMed

LinkOut - more resources